We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Trial Shows Dietary Supplement Can Prevent Hereditary Cancer
News

Trial Shows Dietary Supplement Can Prevent Hereditary Cancer

Trial Shows Dietary Supplement Can Prevent Hereditary Cancer
News

Trial Shows Dietary Supplement Can Prevent Hereditary Cancer

Credit: Emma-Jane Hobden on Unsplash
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Trial Shows Dietary Supplement Can Prevent Hereditary Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A trial in people with a high hereditary risk of a wide range of cancers has shown a major preventive effect from resistant starch, found in a wide range of foods such as oats, breakfast cereal, cooked and cooled pasta or rice, peas, beans and slightly green bananas.


An international trial - known as CAPP2 – involved almost 1000 patients with Lynch syndrome from around the world and revealed that a regular dose of resistant starch, also known as fermentable fibre, taken for an average of two years, did not affect cancers in the bowel but did reduce cancers in other parts of the body by more than half. This effect was particularly pronounced for upper gastrointestinal cancers including oesophageal, gastric, biliary tract, pancreatic and duodenum cancers.


The astonishing effect was seen to last for 10 years after stopping taking the supplement.


The study, led by experts at the Universities of Newcastle and Leeds, published today in Cancer Prevention Research, a journal of the American Association for Cancer Research, is a planned double blind 10 year follow–up, supplemented with comprehensive national cancer registry data for up to 20 years in 369 of the participants.


Previous research published as part of the same trial, revealed that aspirin reduced cancer of the large bowel by 50%.


“We found that resistant starch reduces a range of cancers by over 60%. The effect was most obvious in the upper part of the gut,” explained Professor John Mathers, professor of Human Nutrition at Newcastle University. “This is important as cancers of the upper GI tract are difficult to diagnose and often are not caught early on.


“Resistant starch can be taken as a powder supplement and is found naturally in peas, beans, oats and other starchy foods.  The dose used in the trial is equivalent to eating a daily banana; before they become too ripe and soft, the starch in bananas resists breakdown and reaches the bowel where it can change the type of bacteria that live there.


“Resistant starch is a type of carbohydrate that isn’t digested in your small intestine, instead it ferments in your large intestine, feeding beneficial gut bacteria – it acts in effect, like dietary fibre in your digestive system. This type of starch has several health benefits and fewer calories than regular starch. We think that resistant starch may reduce cancer development by changing the bacterial metabolism of bile acids and to reduce those types of bile acids that can damage our DNA and eventually cause cancer. However, this needs further research.”


Professor Sir John Burn, from Newcastle University and Newcastle Hospitals NHS Foundation Trust who ran the trial with Professor Mathers, said: “When we started the studies over 20 years ago, we thought that people with a genetic predisposition to colon cancer could help us to test whether we could reduce the risk of cancer with either aspirin or resistant starch.


“Patients with Lynch syndrome are high risk as they are more likely to develop cancers so finding that aspirin can reduce the risk of large bowel cancers and resistant starch other cancers by half is vitally important.


“Based on our trial, NICE (The National Institute for Health and Care Excellence) now recommend aspirin for people at high genetic risk of cancer, the benefits are clear – aspirin and resistant starch work.”

Long term study

Between 1999 and 2005, nearly 1000 participants began either taking resistant starch in a powder form every day for two years or aspirin or a placebo.

At the end of the treatment stage, there was no overall difference between those who had taken resistant starch or aspirin and those who had not. However, the research team anticipated a longer-term effect and designed the study for further follow-up.


In the period of follow-up, there were just 5 new cases of upper GI cancers among the 463 participants who had taken the resistant starch compared with 21 among the 455 who were on the placebo.


The team are now leading the international trial, CaPP3, with more than 1,800 people with Lynch syndrome enrolled to look at whether smaller, safer doses of aspirin can be used to help reduce the cancer risk.


Reference: Mathers JC, Elliott F, Macrae F, et al. Cancer prevention with resistant starch in Lynch syndrome patients in the CAPP2-randomized placebo-controlled trial: planned 10-year follow-up. Cancer Prevention Research. 2022:OF1-OF12. doi: 10.1158/1940-6207.CAPR-22-0044


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement